Amarin Corp Plc (AMRN)

[jessellivermore]

zum,

This is a very good article and is a good example of why it is so difficult to extract meaningful clinical effects, from just measuring lipid parameters. The difficulty arises because EPA acts on the desired lipid and changes the function of the lipid without changing the amount of lipid.

For example, EPA could increase the antioxidant capability of a lipid such as HDL-C, which would then result in less oxidation of LDL-C. If a doctor took a blood sample he would see no change in the HDL-C and LDL-C levels, but clearly the clinical situation (the CVD risk) would have changed.

This is something clinicians need to understand. At present there is too much attention placed on the lipid level (amount). It is assumed that only changes in amount are significant when it may be the functional state of the lipid may be as or more important. This issue probably explains a lot of the controversy surrounding lipids including trigs.

":>) JL